Welcome to Prashanth's Lab

Research overview

identification of human diseases, agri-research and microbial classifications is the major focus to us. We have expert in the field of Bioinformatics, Genomics, Proteomics, Molecular biology, Genetics & Drug Discovery, Biostatistical analysis and Bioprogramming such as Data Mining and Artificial Intelligence.

Latest News

  • Prashantha and his team is published research paper on "Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of Coronavirus" in Journal of Molecular Graphics and Modelling.

  • Dr.Veena V, Prashantha and team of students have published research paper on "Atranorin, an antimicrobial metabolite from lichen Parmotrema rampoddense exhibited in vitro anti-breast cancer activity through interaction with Akt activity" in Journal of Biomolecular Structure and Dynamics.

  • Prashantha and his team have successfully submitted "RNA-Seq Analysis of Calotropis Gigantea leaf extract treated with Hela, MCF7 and A549 cancer cell lines" to Sequence Read Archieve (SRA Database).

  • Prashantha and his team is published research article on "Molecular Modelling and Insilico Engineering of PapMV-CP Towards Display and Development of Capripox Viral Like Particles Based on Immunogenic P32 Envelop Protein is the Homologous of the Vaccinia-Viral H3L Gene: An Insilico Approach" in International Journal of Peptide Research and Therapeutics.

  • Prashantha and his team is published research article in preprint journal "In-vitro and Insilico screening platform for the identification of aldose reductase inhibitors for antidiabetic lead compounds from Abutilon Indicum (L.)" in bioRexiv.

  • Prashantha and his team is published research article "Identification and In-silico Prediction of Hermetiaillucens LarvalProtein that Inhibits the Progression of Cervical Cancer" in International Journal of Engineering and Advanced Technology.

Prashantha CN

Assistant Professor

Department of Biotechnology

School of Applied Sciences

REVA University, Bangalore-560064

Email: prashantha.cn@reva.edu.in / prashanthacn@gmail.com

Mobile: +91-9844158444

Few Achievments

  • Experience in Genomics and Bioinformatics for past 12 years

  • Established Scientific Bio-Minds (2008-till date), a Bioinformatics consultancy service providers in India.

  • Established Computational drug discovery facility at 2008.

  • Established Microarray data analysis facility at 2009.

  • Established First NGS Data Analysis service facility at 2011.

  • Established Avious Institute-online training providers at 2012.

  • Established Clovergen Life Sciences Pvt Ltd (2017-till date), a agrigenomic service providers.

  • Provides Bioinformatics, computational drug discovery, NGS & Microarray data analysis training more than 5200 students across globe.

  • Provides internship to more than 800 students on various bioinformatics projects and internship training.

  • Provides more than 1200 consultancy projects on various bioinformatics projects to different clients across work.

Positions held

  • Assistant Professor at REVA University (2018-till date)

  • Co-founder & Managing Director at Clovergen Life Sciences Pvt.Ltd (2017-2018)

  • Proprietor at Avious Institute (2012-2014)

  • Founder CEO & Managing Director at Scientific Bio-Minds (2008-till date)

News Coverage

Predictive Genomics industry is changing at the breath taking pace globally but India is in its early stages (Photo Courtesy: www.the-scientist.com). "The market value for predictive genomics is considered to be about Rs 100 crore," says Dr Raja Mugasimangalam, founder and CEO, Genotypic Technology. Also, an approximate estimate can be drawn based on the US market size which is predicted to grow to as much as $452 billion by 2015. This includes not only the healthcare and pharma markets but also the nutrition and wellness market opportunities that use predictive genomics.

Antibiotic, anti-inflammatory and HIV drugs can inhibit the Sars-CoV-2 virus which causes Covid-19, while anti-malarial medicine is less effective in fighting the disease, a new study has found.

Read more at: https://www.deccanherald.com/national/antibiotics-hiv-drugs-can-inhibit-covid-19-study-912786.html